Nearly one in eight men will be diagnosed with prostate cancer and, as a new UCSF study finds, significantly more of these ...

Advanced prostate cancer cases in California are rising faster than the national average, according to a UCSF study. Experts ...

After a change in screening guidelines, the incidence increased across the state, surpassing the national trend. A new study ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Six months (vs. 3 years) of androgen suppression provided inferior survival for patients with locally advanced disease. Given emerging data about the potential harms of androgen-deprivation ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

In terms of managing prostate cancer, treatments come with two intentions — to cure during the early stage and to prevent progression into advanced stages. Many treatments are available for this type ...

PROSTATE cancer (PCa) screening through serum PSA testing has been shown to significantly reduce mortality rates. The ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Together, they addressed 19 critical questions related to prostate cancer management, including screening, biopsy techniques, handling localized and locally advanced disease, biochemical ...

Chinelo Orji Poster Session A: Prostate Cancer Track Abstract #74 Poster Bd #B20 Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan-treated patients with ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...